New York Life Investment Management LLC Sells 48 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

New York Life Investment Management LLC lowered its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 0.5% during the fourth quarter, HoldingsChannel reports. The fund owned 10,054 shares of the biotechnology company’s stock after selling 48 shares during the quarter. New York Life Investment Management LLC’s holdings in Axon Enterprise were worth $2,597,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of AXON. Sands Capital Management LLC increased its position in Axon Enterprise by 31.1% during the third quarter. Sands Capital Management LLC now owns 2,612,305 shares of the biotechnology company’s stock worth $519,823,000 after acquiring an additional 619,179 shares during the period. Westfield Capital Management Co. LP increased its position in Axon Enterprise by 184.3% during the third quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock worth $138,535,000 after acquiring an additional 451,350 shares during the period. Polar Capital Holdings Plc increased its position in Axon Enterprise by 292.0% during the third quarter. Polar Capital Holdings Plc now owns 265,464 shares of the biotechnology company’s stock worth $52,825,000 after acquiring an additional 197,746 shares during the period. Bank of New York Mellon Corp increased its position in Axon Enterprise by 28.3% during the third quarter. Bank of New York Mellon Corp now owns 726,400 shares of the biotechnology company’s stock worth $144,546,000 after acquiring an additional 160,359 shares during the period. Finally, International Assets Investment Management LLC acquired a new stake in Axon Enterprise during the fourth quarter worth $39,907,000. Institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on AXON. Robert W. Baird lifted their price target on shares of Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a research note on Thursday, February 22nd. TheStreet downgraded shares of Axon Enterprise from a “b” rating to a “c+” rating in a research note on Tuesday, February 27th. Morgan Stanley lifted their price target on shares of Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, April 26th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $323.09.

Axon Enterprise Stock Up 0.6 %

Shares of NASDAQ AXON opened at $318.55 on Monday. The firm’s 50-day simple moving average is $308.83 and its 200 day simple moving average is $265.60. The company has a market cap of $24.04 billion, a price-to-earnings ratio of 138.50 and a beta of 0.91. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42. Axon Enterprise, Inc. has a 12-month low of $175.37 and a 12-month high of $329.87.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.29. The business had revenue of $432.14 million for the quarter, compared to the consensus estimate of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. On average, research analysts expect that Axon Enterprise, Inc. will post 2.44 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.